Literature DB >> 31553824

A QST-based Pain Phenotype in Adults With Sickle Cell Disease: Sensitivity and Specificity of Quality Descriptors.

Brenda W Dyal1, Miriam O Ezenwa1, Saunjoo L Yoon1, Roger B Fillingim2, Yingwei Yao1, Judith M Schlaeger3, Marie L Suarez4, Zaijie J Wang5, Robert E Molokie6,7, Diana J Wilkie1.   

Abstract

BACKGROUND: We sought to refine a screening measure for discriminating a sensitized or normal sensation pain phenotype among African American adults with sickle cell disease (SCD).
OBJECTIVE: To develop scoring schemes based on sensory pain quality descriptors; evaluate their performance on classifying patients with SCD who had sensitization or normal sensation, and compare with scores on the Self-report Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) and the Neuropathic Pain Symptom Inventory (NPSI).
METHODS: Participants completed PAINReportIt, quantitative sensory testing (QST), S-LANSS, and NPSI. Conventional binary logistic regression and least absolute shrinkage and selection operator (lasso) regression were used to obtain 2 sets of weights resulting in 2 scores: the PR-Logistic (PAINReportIt score weighted by conventional binary logistic regression coefficients) and PR-Lasso (PAINReportIt score weighted by lasso regression coefficients). Performance of the proposed scores and the existing scores were evaluated.
RESULTS: Lasso regression resulted in a parsimonious model with non-zero weights assigned to 2 neuropathic descriptors, cold and spreading. We found positive correlations between the PR-Lasso and other scores: S-LANSS (r = 0.22, P < 0.01), NPSI (r = 0.22, P < 0.01), and PR-Logistic (r = 0.35, P < 0.01). The NPSI and PR-Lasso performed similarly at different levels of required specificity and outperformed the S-LANSS and PR-Logistic at the various specificity points.
CONCLUSION: The PR-Lasso offers a way to discriminate a SCD pain phenotype.
© 2019 World Institute of Pain.

Entities:  

Mesh:

Year:  2019        PMID: 31553824      PMCID: PMC7018539          DOI: 10.1111/papr.12841

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  38 in total

Review 1.  Can quantitative sensory testing move us closer to mechanism-based pain management?

Authors:  Yenisel Cruz-Almeida; Roger B Fillingim
Journal:  Pain Med       Date:  2013-09-06       Impact factor: 3.750

2.  Clinical Interpretation of Quantitative Sensory Testing as a Measure of Pain Sensitivity in Patients With Sickle Cell Disease.

Authors:  Amanda M Brandow; Julie A Panepinto
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

3.  Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?

Authors:  Miriam O Ezenwa; Robert E Molokie; Zaijie Jim Wang; Yingwei Yao; Marie L Suarez; Cherese Pullum; Judith M Schlaeger; Roger B Fillingim; Diana J Wilkie
Journal:  Pain Pract       Date:  2015-01-12       Impact factor: 3.183

4.  Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.

Authors:  Deepika S Darbari; Mehdi Nouraie; James G Taylor; Carlo Brugnara; Oswaldo Castro; Samir K Ballas
Journal:  Eur J Haematol       Date:  2014-01-30       Impact factor: 2.997

5.  Relationship of Pain Quality Descriptors and Quantitative Sensory Testing: Sickle Cell Disease.

Authors:  Brenda W Dyal; Miriam O Ezenwa; Saunjoo L Yoon; Roger B Fillingim; Yingwei Yao; Judith M Schlaeger; Marie L Suarez; Zaijie J Wang; Robert E Molokie; Diana J Wilkie
Journal:  Nurs Res       Date:  2019 Sep/Oct       Impact factor: 2.381

6.  Neuropathic pain in patients with sickle cell disease: a cross-sectional study assessing teens and young adults.

Authors:  Fabricio Dias Antunes; Vynicius Goltran Sobral Propheta; Hulemar Andrade Vasconcelos; Rosana Cipolotti
Journal:  Ann Hematol       Date:  2017-03-30       Impact factor: 3.673

7.  An Evaluation of Central Sensitization in Patients With Sickle Cell Disease.

Authors:  Claudia M Campbell; Gyasi Moscou-Jackson; C Patrick Carroll; Kasey Kiley; Carlton Haywood; Sophie Lanzkron; Matthew Hand; Robert R Edwards; Jennifer A Haythornthwaite
Journal:  J Pain       Date:  2016-02-16       Impact factor: 5.820

8.  Sensitivities to Thermal and Mechanical Stimuli: Adults With Sickle Cell Disease Compared to Healthy, Pain-Free African American Controls.

Authors:  Robert E Molokie; Zaijie J Wang; Yingwei Yao; Keesha L Powell-Roach; Judith M Schlaeger; Marie L Suarez; David A Shuey; Veronica Angulo; Jesus Carrasco; Miriam O Ezenwa; Roger B Fillingim; Diana J Wilkie
Journal:  J Pain       Date:  2019-11-13       Impact factor: 5.820

9.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

10.  Pain in children and adolescents with sickle cell disease: a descriptive study.

Authors:  G A Walco; C D Dampier
Journal:  J Pediatr Psychol       Date:  1990-10
View more
  2 in total

Review 1.  Pain in sickle cell disease: current and potential translational therapies.

Authors:  Varun Sagi; Aditya Mittal; Huy Tran; Kalpna Gupta
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

2.  A Stress and Pain Self-management mHealth App for Adult Outpatients With Sickle Cell Disease: Protocol for a Randomized Controlled Study.

Authors:  Miriam O Ezenwa; Yingwei Yao; Molly W Mandernach; David A Fedele; Robert J Lucero; Inge Corless; Brenda W Dyal; Mary H Belkin; Abhinav Rohatgi; Diana J Wilkie
Journal:  JMIR Res Protoc       Date:  2022-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.